VRCA · NASDAQ
Verrica Pharmaceuticals (VRCA) Stock Price & Fundamentals
Verrica Pharmaceuticals (VRCA) closed at $182.42 on Oct 9, 2026, down 0.71% from the previous close of $183.73.
Share price, past year
1Y +2.28%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $182.42 |
| Sep 30, 2026 | $179.61 |
| Aug 31, 2026 | $167.34 |
| Jul 31, 2026 | $163.46 |
| Jun 30, 2026 | $163.57 |
| May 29, 2026 | $169.29 |
| Apr 30, 2026 | $175.93 |
| Mar 31, 2026 | $182.82 |
| Feb 27, 2026 | $167.54 |
| Jan 30, 2026 | $166.24 |
| Dec 31, 2025 | $166.28 |
| Nov 28, 2025 | $174.63 |
| Oct 31, 2025 | $175.91 |
Key statistics
- Market cap
- $3.13B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.74
- Revenue (TTM)
- $30.32M
- Net income (TTM)
- −$31.18M
- Shares outstanding
- 17.2M
- Dividend yield
- —
- 52-week range
- $160.38 – $185.25
Verrica Pharmaceuticals's market cap is $3.13B, based on a share price of $182.42 and 17.2M shares outstanding as of Jun 30, 2026.
Financials
Verrica Pharmaceuticals reported revenue of $35.58M for fiscal 2025, up 370.22% from fiscal 2024.
Verrica Pharmaceuticals reported a net loss of $17.89M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $35.58M | +370.2% | −$17.89M | −50.3% | −$1.68 | −$17.63M |
| FY2024ended Dec 31, 2024 | $7.57M | +47.7% | −$76.58M | −1,012.2% | −$14.78 | −$60.95M |
| FY2023ended Dec 31, 2023 | $5.12M | −43.3% | −$67.00M | −1,307.5% | −$14.80 | −$38.94M |
| FY2022ended Dec 31, 2022 | $9.03M | −24.7% | −$24.49M | −271.1% | −$7.20 | −$18.95M |
| FY2021ended Dec 31, 2021 | $12.00M | — | −$35.08M | −292.3% | −$13.00 | −$28.47M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $5.86M | −$13.15M | −$0.62 |
| Q1 FY2026ended Mar 31, 2026 | $5.02M | −$9.68M | −$0.45 |
| Q4 FY2025ended Dec 31, 2025 | $5.09M | −$8.07M | −$0.64 |
| Q3 FY2025ended Sep 30, 2025 | $14.34M | −$274.00K | −$0.03 |
| Q2 FY2025ended Jun 30, 2025 | $12.70M | $204.00K | $0.02 |
| Q1 FY2025ended Mar 31, 2025 | $3.44M | −$9.74M | −$1.03 |
| Q4 FY2024ended Dec 31, 2024 | $344.00K | −$16.20M | −$1.80 |
| Q3 FY2024ended Sep 30, 2024 | −$1.78M | −$22.86M | −$4.88 |
Company profile
- Name
- Verrica Pharmaceuticals Inc.
- Ticker
- VRCA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 44 West Gay Street, Suite 400, West Chester, PA
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001660334
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 9, 2026
- May 12, 2026
- May 12, 2026
- Mar 11, 2026
- Mar 11, 2026
- Dec 30, 2025
Frequently asked questions
What is Verrica Pharmaceuticals's stock price?
Verrica Pharmaceuticals (VRCA) closed at $182.42 on Oct 9, 2026, down 0.71% from the previous close of $183.73.
What is Verrica Pharmaceuticals's market cap?
Verrica Pharmaceuticals's market cap is $3.13B, based on a share price of $182.42 and 17.2M shares outstanding as of Jun 30, 2026.
How much revenue does Verrica Pharmaceuticals make?
Verrica Pharmaceuticals reported revenue of $35.58M for fiscal 2025, up 370.22% from fiscal 2024.
Does Verrica Pharmaceuticals pay a dividend?
Verrica Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Verrica Pharmaceuticals Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures